X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA WYETH LTD ELDER PHARMA/
WYETH LTD
 
P/E (TTM) x -0.2 27.7 - View Chart
P/BV x 0.1 5.3 1.9% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 ELDER PHARMA   WYETH LTD
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
WYETH LTD
Mar-13
ELDER PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs3801,044 36.4%   
Low Rs188818 23.0%   
Sales per share (Unadj.) Rs491.2298.6 164.5%  
Earnings per share (Unadj.) Rs-3.257.2 -5.6%  
Cash flow per share (Unadj.) Rs14.458.4 24.7%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs376.5249.5 150.9%  
Shares outstanding (eoy) m20.5422.72 90.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.1 18.5%   
Avg P/E ratio x-89.316.3 -548.7%  
P/CF ratio (eoy) x19.715.9 123.6%  
Price / Book Value ratio x0.83.7 20.2%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m5,83321,157 27.6%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m2,179400 544.8%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m10,0896,783 148.7%  
Other income Rs m257353 72.8%   
Total revenues Rs m10,3467,136 145.0%   
Gross profit Rs m-7921,617 -49.0%  
Depreciation Rs m36127 1,358.3%   
Interest Rs m2,7566 50,114.5%   
Profit before tax Rs m-3,6531,938 -188.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,713-5 -72,798.0%   
Tax Rs m125632 19.8%   
Profit after tax Rs m-651,301 -5.0%  
Gross profit margin %-7.823.8 -32.9%  
Effective tax rate %-3.432.6 -10.5%   
Net profit margin %-0.619.2 -3.4%  
BALANCE SHEET DATA
Current assets Rs m9,2406,984 132.3%   
Current liabilities Rs m9,9982,056 486.3%   
Net working cap to sales %-7.572.6 -10.3%  
Current ratio x0.93.4 27.2%  
Inventory Days Days4699 46.7%  
Debtors Days Days6024 250.4%  
Net fixed assets Rs m10,124244 4,144.0%   
Share capital Rs m206227 90.5%   
"Free" reserves Rs m5,5825,441 102.6%   
Net worth Rs m7,7345,668 136.4%   
Long term debt Rs m4,88925 19,556.0%   
Total assets Rs m22,8827,901 289.6%  
Interest coverage x-0.3353.3 -0.1%   
Debt to equity ratio x0.60 14,332.9%  
Sales to assets ratio x0.40.9 51.4%   
Return on assets %11.816.5 71.1%  
Return on equity %-0.822.9 -3.7%  
Return on capital %22.334.0 65.5%  
Exports to sales %3.00.2 1,392.9%   
Imports to sales %0.436.3 1.2%   
Exports (fob) Rs m30715 2,071.6%   
Imports (cif) Rs m432,465 1.7%   
Fx inflow Rs m30715 2,017.1%   
Fx outflow Rs m1252,677 4.7%   
Net fx Rs m181-2,662 -6.8%   
CASH FLOW
From Operations Rs m11,754923 1,273.2%  
From Investments Rs m-561317 -176.9%  
From Financial Activity Rs m-6,762-481 1,405.8%  
Net Cashflow Rs m4,432759 583.8%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 7.5 11.3 66.4%  
FIIs % 16.8 7.2 233.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 30.4 118.8%  
Shareholders   16,479 21,978 75.0%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS